| 1.64 0.03 (1.86%) | 04-29 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.22 | 1-year : | 3 |
| Resists | First : | 1.9 | Second : | 2.56 |
| Pivot price | 1.38  |
|||
| Supports | First : | 0.82 | Second : | 0.68 |
| MAs | MA(5) : | 1.75 |
MA(20) : | 1.4  |
| MA(100) : | 2.05 |
MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 71.5 |
D(3) : | 78.2 |
| RSI | RSI(14): 52.2 |
|||
| 52-week | High : | 5.5 | Low : | 0.77 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NKGN ] has closed below upper band by 29.0%. Bollinger Bands are 2.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.9 - 1.91 | 1.91 - 1.92 |
| Low: | 1.6 - 1.61 | 1.61 - 1.62 |
| Close: | 1.63 - 1.64 | 1.64 - 1.65 |
Graf Acquisition Corp. IV does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. Graf Acquisition Corp. IV was incorporated in 2021 and is based in The Woodlands, Texas.
Mon, 29 Apr 2024
Midday Stock Roundup: Shimmick Shares Fall by Half - Orange County Business Journal
Tue, 23 Apr 2024
NKGN Stock Price and Chart — NASDAQ:NKGN - TradingView
Wed, 06 Mar 2024
Why Is NKGen Biotech (NKGN) Stock Up 62% Today? - InvestorPlace
Tue, 14 Nov 2023
NKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights - Yahoo Finance
Mon, 02 Oct 2023
NKGen Biotech Stock (NASDAQ:NKGN), Quotes and News Summary - Benzinga
Mon, 02 Oct 2023
NKGen Biotech, Inc. Announces Closing of Business Combination - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 23 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 57.7 (%) |
| Held by Institutions | 17.1 (%) |
| Shares Short | 622 (K) |
| Shares Short P.Month | 336 (K) |
| EPS | -5.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.87 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.12 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -20 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.31 |
| PEG Ratio | 0 |
| Price to Book value | -0.89 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.83 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|